Integration of network pharmacology, UHPLC-Q Exactive Orbitrap HRMS technique and metabolomics to elucidate the active ingredients and mechanisms of Compound Danshen Pills in treating hypercholesterolemic rats

Hypercholesterolemia (HLC) was a key risk factor for cardiovascular disease (CVD) characterized by elevated cholesterol levels, particularly LDL. While traditional Chinese medicine preparations Compound Danshen Pills(CDP) has been clinically used for hypercholesterolemia and coronary heart disease, its specific therapeutic effect on HLC remains understudied, necessitating further investigation into its mechanisms.